Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial
TL;DR
Novavax announced that its COVID-19-Influenza combination and stand-alone influenza vaccines elicited strong immune responses and were well tolerated in a Phase 3 trial involving adults aged 65 and older, with results comparable to existing licensed vaccines, supporting further development and partnership discussions.
Want the full story? Read the original reporting
Read on Novavax Investor Relations